Inhaled treprostinil is an effective, well-tolerated add-on therapy for patients with pulmonary arterial hypertension (PAH) treated with bosentan

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1561, 2006-01, pp. : 14-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sitaxsentan sodium appears to be more cost effective than bosentan in treating patients with pulmonary arterial hypertension (PAH)

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 508, 2006-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Bosentan may be an effective therapy for patients with chronic thromboembolic pulmonary hypertension

By  

Inpharma, Vol. 1, Iss. 1605, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Bosentan: In Pediatric Patients with Pulmonary Arterial Hypertension

By Carter Natalie J.   Keating Gillian M.  

Pediatric Drugs, Vol. 12, Iss. 1, 2010-02 ,pp. : 63-73

Adis International

Access to resources Recommend Favorite

Eptacog-alfa [activated recombinant factor VII] is an effective, well-tolerated therapy in haemophilia patients with inhibitors

By  

Inpharma, Vol. 1, Iss. 1572, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Treprostinil therapy for pulmonary artery hypertension

By Horn Evelyn M   Barst Robyn J  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 11, 2002-11 ,pp. : 1615-1622

Informa Healthcare

Access to resources Recommend Favorite